Jeremy Loy, OD
Optometrist · Fort Worth, TXNPI 1710970256
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,000 of the $3,777 with a category attached, or 79.4%. Eyevance Pharmaceuticals LLC accounts for 83.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,065 and has fallen 89.5% since, to $216 in 2025.
Across 34 payments — averaging $111.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$3K
- Alcon$191
- Johnson & Johnson Vision Care, Inc.$127
- Glaukos Corporation$111
- Coopervision Inc.$53
- Dompe US, Inc.$52
- plus $99 from 4 others
What the payments were for
- Consulting fees$3,00079%
- Food & beverage$77721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 10 | $3,144 |
| Alcon | 9 | $191 |
| Johnson & Johnson Vision Care, Inc. | 6 | $127 |
| Glaukos Corporation | 1 | $111 |
| Coopervision Inc. | 3 | $53 |
| Dompe US, Inc. | 1 | $52 |
| Biotissue Holdings Inc. | 1 | $30 |
| ABB Con-cise Optical Group LLC | 1 | $24 |
| Novartis | 1 | $24 |
| Sight Sciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,777 in reported general payments places this provider in the 85th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 68 | $810 |
| Dorzolamide Hcl | 22 | $302 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $235 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $151 |
| Timolol Maleate | 17 | $92 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Fort Worth
- Kenneth KingFort Worth$39K
- Robert ChuFort Worth$30K
- Jennifer DeakinsFort Worth$23K
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.